zinc finger protein 90 pseudogene 1Genealiases: ZNF108 · ZNF108P
Q-omics provides the consensus-scored ZNF90P1 profile across patient tissues and cancer cell-line models. ZNF90P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF90P1 is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, ZNF90P1 RNA expression shows 11,947 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, CHOL, and GBM as cancer lineages where ZNF90P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF90P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF90P1 survival associations across molecular data types. ZNF90P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF90P1 RNA expression–survival associations across cancer types. High ZNF90P1 expression shows unfavorable associations in LIHC, STAD, MESO and SARC, but favorable associations in LUAD and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF90P1 RNA expression.
This table summarizes ZNF90P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF90P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF90P1 shows lower tumor expression in KICH and KIRC and higher tumor expression in CHOL, COAD and HNSC. The CHOL box plot shows higher ZNF90P1 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .034).
This table shows molecular features associated with ZNF90P1 in patient tissues and cancer cell lines. In patient samples, ZNF90P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
